MedTrace Logo

Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma

NCT02267213 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2019-02-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of TLC388 (Lipotecan) as a second line treatment in subjects with advanced Hepatocellular Carcinoma.

Conditions

Interventions

DRUG

Lipotecan

Administer 40mg Lipotecan at D1, D8, D15 of each cycle.

Sponsors & Collaborators

  • Taiwan Liposome Company

    lead INDUSTRY

Principal Investigators

  • Yunlong Tseng · Taiwan Liposome Company

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-10
Primary Completion
2015-07-09
Completion
2015-07-09

Countries

  • China
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02267213 on ClinicalTrials.gov